Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
2.
J Am Acad Dermatol ; 75(4): 774-781, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27476106

ABSTRACT

BACKGROUND: Chronic itch is a disruptive and disabling condition that can lead to psychological stress and depression. OBJECTIVE: We sought to describe an entity of generalized, symmetric, neuropathic pruritus, which we term "multilevel symmetric neuropathic pruritus," and offer possible explanations accounting for its pathogenesis. METHODS: A case series of 14 patients was evaluated at academic institutions from 2011 to 2015. RESULTS: All patients exhibited detectable degenerative vertebral changes, as seen by spinal x-ray or magnetic resonance imaging. In 12 of 14 (85.7%) subjects, the radiographic imaging abnormalities directly correlated with the distribution of their cutaneous findings. Twelve of 14 (85.7%) patients had cutaneous findings along the C5 to C6 and/or C6 to C7 dermatomal distributions. Eleven of 14 (78.5%) patients were overweight or obese, and 14 of 14 (100%) patients had at least 4 risk factors for the development of atherosclerosis. Twelve of 14 (85.7%) patients noted complete or near complete resolution after treatment with gabapentin (300-1200 mg daily). LIMITATIONS: No healthy age-matched control group without pruritus was investigated. CONCLUSION: A combination of multilevel degenerative disc disease of the spine, spinal nerve root impingement, and/or nerve root traction may play a pivotal role in the cause of multilevel symmetric neuropathic pruritus.


Subject(s)
Peripheral Nervous System Diseases/complications , Pruritus/etiology , Pruritus/physiopathology , Quality of Life , Age Distribution , Aged , Amines/therapeutic use , Chronic Disease , Cohort Studies , Cyclohexanecarboxylic Acids/therapeutic use , Disease Progression , Female , Gabapentin , Humans , Incidence , Male , Middle Aged , Prognosis , Pruritus/epidemiology , Pruritus/psychology , Retrospective Studies , Risk Assessment , Severity of Illness Index , Sex Distribution , gamma-Aminobutyric Acid/therapeutic use
3.
Cutis ; 98(6): E12-E15, 2016 Dec.
Article in English | MEDLINE | ID: mdl-28099546

ABSTRACT

Keratoacanthomas (KAs) are common skin lesions known for their rapid growth and spontaneous regression. Keratoacanthomas also can occur in sites of prior trauma, such as surgical scars. We report a case of multiple KAs occurring in the site of trauma from a prior surgery and de novo as well as the response to treatment with intralesional methotrexate (MTX).


Subject(s)
Dermatologic Agents/administration & dosage , Keratoacanthoma/diagnosis , Methotrexate/administration & dosage , Cicatrix/pathology , Humans , Injections, Intralesional , Keratoacanthoma/drug therapy , Keratoacanthoma/pathology , Male , Margins of Excision , Middle Aged
4.
Cytokine ; 73(2): 319-25, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25541432

ABSTRACT

Much work has been done to unveil the mechanisms behind the pathogenesis of dermatomyositis (DM) - mainly those involving certain pathogenic cytokines, termed "pathokines" as the principal cytokines involved. Recently, it has become clear that a group of cytokines known as type I interferons (IFN-Is) play a significant role in the development of DM. We review the literature published between 1946 and 2014 using an Ovid Medline database search to provide an update on the role of IFN-Is and other cytokines in the pathogenesis of DM. We provide information about the genes and proteins induced by IFN-Is and potential mechanisms by which these downstream products relate to clinical disease activity. We also explore findings of other autoimmune phenomena that may contribute to disease onset and activity including T-helper 17 (Th17) cells and associated interleukins, as well as autoantibodies. Finally, we provide a brief update on current treatment options for DM as well as some new immunomodulatory treatment modalities in development.


Subject(s)
Dermatomyositis/immunology , Interferon Type I/metabolism , Autoantibodies/immunology , Dermatomyositis/physiopathology , Dermatomyositis/therapy , Humans , Models, Biological , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL
...